These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28126200)

  • 41. [Clinical significance and shortcoming of classification of asthma severity].
    Lin JT; Zhong NS
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Mar; 28(3):145-6. PubMed ID: 15854406
    [No Abstract]   [Full Text] [Related]  

  • 42. [Does phenotyping asthma help to improve differential treatment?].
    Taube C; Buhl R
    Dtsch Med Wochenschr; 2010 Mar; 135(10):468-73. PubMed ID: 20198546
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma.
    Milgrom H; Fowler-Taylor A; Vidaurre CF; Jayawardene S
    Curr Med Res Opin; 2011 Jan; 27(1):163-9. PubMed ID: 21121874
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum IgE Induced Airway Smooth Muscle Cell Remodeling Is Independent of Allergens and Is Prevented by Omalizumab.
    Roth M; Zhao F; Zhong J; Lardinois D; Tamm M
    PLoS One; 2015; 10(9):e0136549. PubMed ID: 26332463
    [TBL] [Abstract][Full Text] [Related]  

  • 45. After 6 years with Xolair; a 3-year withdrawal follow-up.
    Nopp A; Johansson SG; Adédoyin J; Ankerst J; Palmqvist M; Oman H
    Allergy; 2010 Jan; 65(1):56-60. PubMed ID: 19796193
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Two inflammatory phenotypes of nasal polyps and comorbid asthma.
    Wu D; Li L; Zhang M; Wang J; Wei Y
    Ann Allergy Asthma Immunol; 2017 Mar; 118(3):318-325. PubMed ID: 28126433
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of anthraquinones from Cassia occidentalis L. on ovalbumin-induced airways inflammation in a mouse model of allergic asthma.
    Xu W; Hu M; Zhang Q; Yu J; Su W
    J Ethnopharmacol; 2018 Jul; 221():1-9. PubMed ID: 29649507
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Three months' administration of anti-IgE to a patient with Churg-Strauss syndrome.
    Giavina-Bianchi P; Giavina-Bianchi M; Agondi R; Kalil J
    J Allergy Clin Immunol; 2007 May; 119(5):1279; author reply 1279-80. PubMed ID: 17349685
    [No Abstract]   [Full Text] [Related]  

  • 49. Influence of Omalizumab on Allergen-Specific IgE in Patients with Adult Asthma.
    Mizuma H; Tanaka A; Uchida Y; Fujiwara A; Manabe R; Furukawa H; Kuwahara N; Fukuda Y; Kimura T; Jinno M; Ohta S; Yamamoto M; Matsukura S; Adachi M; Sagara H
    Int Arch Allergy Immunol; 2015; 168(3):165-72. PubMed ID: 26790100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phenotypes and endotypes of uncontrolled severe asthma: new treatments.
    Campo P; Rodríguez F; Sánchez-García S; Barranco P; Quirce S; Pérez-Francés C; Gómez-Torrijos E; Cárdenas R; Olaguibel JM; Delgado J; ;
    J Investig Allergol Clin Immunol; 2013; 23(2):76-88; quiz 1 p. follow 88. PubMed ID: 23654073
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Severe childhood asthma: a common international approach?
    Bush A; Hedlin G; Carlsen KH; de Benedictis F; Lodrup-Carlsen K; Wilson N
    Lancet; 2008 Sep; 372(9643):1019-21. PubMed ID: 18805316
    [No Abstract]   [Full Text] [Related]  

  • 52. [Omalizumab, an anti-IgE monoclonal antibody to treat severe asthma].
    Michils A; Sternon J
    J Pharm Belg; 2006; 61(3):83-7. PubMed ID: 17058881
    [TBL] [Abstract][Full Text] [Related]  

  • 53. As strong as an OX or as weak as a kitten?
    Brightling C
    Clin Exp Allergy; 2014 Jan; 44(1):6-8. PubMed ID: 24355016
    [No Abstract]   [Full Text] [Related]  

  • 54. Effect of omalizumab treatment in a baker with occupational asthma.
    Pérez Pimiento A; Bueso Fernández A; García Loria J; Rodríguez Cabreros MI; Mosquera MR; García Cubero A
    J Investig Allergol Clin Immunol; 2008; 18(6):490-1. PubMed ID: 19123449
    [No Abstract]   [Full Text] [Related]  

  • 55. Impact of inadequately controlled asthma: a need for targeted therapy?
    Mehlhop PD; Blake K
    J Clin Pharm Ther; 2004 Jun; 29(3):189-94. PubMed ID: 15153080
    [No Abstract]   [Full Text] [Related]  

  • 56. The PEAK study: does pharmaceutical care make a difference?
    Osborn TM; Redding G
    J Am Pharm Assoc (2003); 2003; 43(5):548, 550. PubMed ID: 14626741
    [No Abstract]   [Full Text] [Related]  

  • 57. Omalizumab as add-on therapy to inhaled steroids for asthma.
    Hadj Tahar A
    Issues Emerg Health Technol; 2004 Jun; (58):1-4. PubMed ID: 15455487
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The future of asthma therapy].
    Solèr M
    Schweiz Med Wochenschr; 2000 Feb; 130(8):277-81. PubMed ID: 10726286
    [TBL] [Abstract][Full Text] [Related]  

  • 59. World Asthma and COPD Forum. Clinical trial results with omalizumab.
    D'Amato G
    IDrugs; 2008 Jul; 11(7):489-92. PubMed ID: 18600594
    [No Abstract]   [Full Text] [Related]  

  • 60. [Severe asthma, IgE and anti-IgE: from sceptical waiting to factual learning].
    Blanc FX
    Rev Mal Respir; 2005 Dec; 22(6 Pt 1):925-7. PubMed ID: 16220115
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.